Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership

Fibronostics and the Fatty Liver Foundation are pleased to announce they have entered into a strategic collaboration, combining Fibronostics’ industry leading in vitro diagnostics platform for metabolic conditions with the Fatty Liver Foundation broad outreach to patients, to help identify asymptomatic, undiagnosed liver injuries and to educate patients on the lifestyle changes needed to halt or minimize disease progression.

Non-alcoholic fatty liver disease (NAFLD) is a growing epidemiologic burden on our health care system. The more aggressive form of NAFLD, non-alcoholic steatohepatitis (NASH), has been linked to increased morbidity and mortality. NASH accounts for about 20-25% of all NAFLD patients and can be challenging to diagnose. Identifying those patients at greatest risk for NASH and disease progression is the first step in preventing progression to cirrhosis and liver decompensation. LIVERFASt™ uniquely gives an opportunity to identify these patients and direct them to appropriate care that may help prevent progression of their disease.

Recommended AI News: Sesame Software Announces Fully Automated Connectors to Accelerate Data Loading Into Amazon Redshift

Related Posts
1 of 40,447

“Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and a lack of pharmacological agents with proven efficacy. LIVERFASt™ aids healthcare providers with diagnosis information on all three lesions, enabling a more proactive management of patients with NAFLD, T2DM and NASH,” said Roni Amiel, CEO of Fibronostics.

Recommended AI News: Huobi Labuan Launches in Malaysia to Provide Locals With Regulated Digital Asset Trading Services

“We are very pleased to enter into this strategic collaboration with Fibronostics,” said Wayne Eskridge, President and CEO of Fatty Liver Foundation. “This collaboration furthers FLF’s patient outreach activities to enable transformative change by expanding the role and impact of early identification of asymptomatic, undiagnosed NASH and to educate patients on the lifestyle changes and other interventions needed to halt or minimize disease progression.”

Recommended AI News: DefinedCrowd Announces Expanded Datasets for European Languages

3 Comments
  1. TheodoreTH009 says

    Speaking of tackling complex problems, whether in healthcare or academics, I’ve found that having the right support is crucial. For instance, when dealing with challenging math problems I turned to the site for help. They offer solutions for those of us asking someone to do my math problem, providing clear, step-by-step assistance that demystifies complex issues. It’s all about finding the right expertise to navigate through complicated scenarios, whether in health or education.

  2. Copper scrap auction says

    Copper scrap shipment tracking Scrap copper recycling center Scrap metal profit margins
    Copper cable scrap standards, Sustainable metal scrap processing, Copper scrap yard prices

  3. Scrap iron reclaiming says

    Demolition metal recycling Ferrous waste reclamation and processing Iron recycling management

    Ferrous material reliability, Iron reclamation depot, Metal reclamation and reprocessing

Leave A Reply

Your email address will not be published.